Key result
Elevated serum sLOX-1 is linked to larger infarct volume and worse outcomes in ischemic stroke.
Why the study?
Does LOX-1 degradation via neuronal autophagy alleviate cerebral ischemia/reperfusion injury in mice and correlate with outcomes in acute ischemic stroke patients?
Observational (n=295)
Does LOX-1 degradation via neuronal autophagy alleviate cerebral ischemia/reperfusion injury in mice and correlate with outcomes in acute ischemic stroke patients?
LOX-1 exacerbates cerebral ischemia/reperfusion injury by inhibiting neuronal autophagic flux, and its degradation via autophagy activation offers a potential neuroprotective strategy.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is critically involved in atherosclerotic plaque formation. Recent clinical evidence suggest that the LOX-1 polymorphisms are linked to the susceptibility and outcomes of ischemic stroke (IS). However, the mechanisms through which LOX-1 influences cerebral ischemia/reperfusion (I/R) injury are not fully understood. In this study, blood samples were obtained from 295 patients with acute IS (AIS), and parallel experimental models including middle cerebral artery occlusion and reperfusion (MCAO/R) in male C57BL/6 mice and oxygen glucose deprivation (OGD) in primary neurons, were used to simulate cerebral I/R injury. Elevated serum soluble LOX-1 (sLOX-1) levels were detected in patients with AIS and showed positive correlations with both infarct volume and the 3-month modified Rankin scale (mRS) score. In mice, LOX-1 overexpression increased infarct volume, aggravated neurological deficits, and reduced cerebral blood flow (CBF), whereas LOX-1 knockdown produced the opposite effects. Co-immunoprecipitation demonstrated that LOX-1 interacts with key autophagy-lysosome pathway proteins (LC3B, P62, and LAMP2) in primary neurons. Western blotting, immunofluorescence and transmission electron microscopy showed that LOX-1 overexpression suppresses neuronal autophagic flux in peri-infarct brain tissue, while LOX-1 knockdown restores it. Moreover, early activation of autophagy with rapamycin (RAPA) promoted LOX-1 degradation, reduced infarct volume, improved neurological deficits, and restored CBF following cerebral I/R. Collectively, these findings indicated that LOX-1 exacerbates cerebral I/R injury by inhibiting neuronal autophagic flux. Early autophagy activation may therefore represent a promising neuroprotective strategy by facilitating LOX-1 degradation during acute cerebral ischemia.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) conducted an observational in Acute ischemic stroke (n=295). Elevated serum soluble LOX-1 (sLOX-1) levels was evaluated on Infarct volume and 3-month modified Rankin scale (mRS) score. Elevated serum sLOX-1 levels in acute ischemic stroke patients positively correlated with infarct volume and 3-month mRS scores, while animal models showed LOX-1 exacerbates injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: